Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
Key Highlights
- ➤LB2501 produced 100% overall and complete response rates among eight DL2 patients
- ➤CARTITUDE-4 showed nearly 60% progression-free at 30 months after CARVYKTI infusion
- ➤CITADEL reduced IEC-parkinsonism rate to 1.6% versus 2.9% historical data
- ➤CARVYKTI early-line subgroup median overall survival had not been reached
- ➤LUCAR-G39D follow-up data will cover an allogeneic dual-targeted CAR-T candidate
Expert Statements
Ingrid Zhang, Chief Executive Officer of Legend Biotech
“The data we will present at ASH reflect the continued evolution of CARVYKTI and our work to advance the next generation of cell therapy”
Ingrid Zhang, Chief Executive Officer of Legend Biotech
“As we continue to build on the impact of CARVYKTI in multiple myeloma, we are advancing new approaches, including in vivo CAR-T, that could expand what is possible with cell therapy and ultimately bring its potential to more patients.”
* New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatment * Updated data to be presented from first-in-human trial of LB2501, an investigational, off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells BRIDGEWATER, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that multiple abstracts were accepted for the 2026 American Society of Hematology (ASH) Annual Meeting, taking place December 12–15 in New Orleans, Louisiana. The presentations will highlight new clinical and real-world analyses of CARVYKTI(®) (ciltacabtagene autoleucel; cilta-cel) in multiple myeloma, as well as updated data from Legend Biotech’s next-generation cell therapy programs. The program includes two oral presentations, four posters, and an additional ePublication.
Get started
Create a free account to read the full story.